

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 10-Q**

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended February 28, 2025.

or

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 0-17988



**Neogen Corporation**

(Exact name of registrant as specified in its charter)

Michigan  
(State or other jurisdiction of  
incorporation or organization)

38-2367843  
(IRS Employer  
Identification Number)

620 Leshar Place  
Lansing, Michigan 48912  
(Address of principal executive offices, including zip code)  
(517) 372-9200  
(Registrant's telephone number, including area code)

**SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:**

Title of each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.16 par value per share	NEOG	NASDAQ Global Select Market
	N/A	

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller Reporting Company	<input type="checkbox"/>
Emerging growth company	<input type="checkbox"/>		

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): YES ☐ NO ☒

As of February 28, 2025 there were 217,038,267 shares of Common Stock outstanding.

**NEOGEN CORPORATION**  
**TABLE OF CONTENTS**

	<u>Page No.</u>
<b><u>PART I. FINANCIAL INFORMATION</u></b>	
Item 1. <a href="#"><u>Interim Condensed Consolidated Financial Statements (unaudited)</u></a>	2
<a href="#"><u>Condensed Consolidated Balance Sheets – February 28, 2025 and May 31, 2024</u></a>	2
<a href="#"><u>Condensed Consolidated Statements of Operations – Three and nine months ended February 28, 2025 and February 29, 2024</u></a>	3
<a href="#"><u>Condensed Consolidated Statements of Comprehensive (Loss) Income – Three and nine months ended February 28, 2025 and February 29, 2024</u></a>	4
<a href="#"><u>Condensed Consolidated Statements of Equity – Three and nine months ended February 28, 2025 and February 29, 2024</u></a>	5
<a href="#"><u>Condensed Consolidated Statements of Cash Flows – Nine months ended February 28, 2025 and February 29, 2024</u></a>	6
<a href="#"><u>Notes to Interim Condensed Consolidated Financial Statements – February 28, 2025</u></a>	7
Item 2. <a href="#"><u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u></a>	18
Item 3. <a href="#"><u>Quantitative and Qualitative Disclosures About Market Risk</u></a>	30
Item 4. <a href="#"><u>Controls and Procedures</u></a>	31
<b><u>PART II. OTHER INFORMATION</u></b>	
Item 1. <a href="#"><u>Legal Proceedings</u></a>	32
Item 1A. <a href="#"><u>Risk Factors</u></a>	32
Item 2. <a href="#"><u>Unregistered Sales of Equity Securities and Use of Proceeds</u></a>	32
Item 5. <a href="#"><u>Other Information</u></a>	32
Item 6. <a href="#"><u>Exhibits</u></a>	33
<b><u>SIGNATURES</u></b>	34
<b>CEO Certification</b>	
<b>CFO Certification</b>	
<b>Section 906 Certification</b>	

## PART I – FINANCIAL INFORMATION

### Item 1. Interim Condensed Consolidated Financial Statements

#### Neogen Corporation Condensed Consolidated Balance Sheets (in thousands, except shares)

	February 28, 2025	May 31, 2024
	(unaudited)	
<b>Assets</b>		
<b>Current Assets</b>		
Cash and cash equivalents	\$ 127,705	\$ 170,611
Marketable securities	—	325
Accounts receivable, net of allowance of \$5,305 and \$4,140	160,068	173,005
Inventories		
Raw materials	75,047	78,799
Work-in-process	14,305	10,990
Finished goods	136,250	111,839
	225,602	201,628
Less inventory reserve	(20,160)	(12,361)
Inventories, net	205,442	189,267
Prepaid expenses and other current assets	58,498	56,025
<b>Total Current Assets</b>	<b>551,713</b>	<b>589,233</b>
<b>Net Property and Equipment</b>	<b>327,838</b>	<b>277,104</b>
<b>Other Assets</b>		
Right of use assets	17,314	14,785
Goodwill (note 5)	1,671,705	2,135,632
Intangible assets, net	1,439,237	1,511,653
Other non-current assets	28,529	20,426
<b>Total Assets</b>	<b>\$ 4,036,336</b>	<b>\$ 4,548,833</b>
<b>Liabilities and Stockholders' Equity</b>		
<b>Current Liabilities</b>		
Current portion of finance lease	\$ 2,501	\$ 2,447
Accounts payable	72,240	83,061
Accrued compensation	18,335	19,949
Income tax payable	12,924	10,449
Accrued interest	3,438	10,985
Deferred revenue	5,769	4,632
Other current liabilities	25,993	22,800
<b>Total Current Liabilities</b>	<b>141,200</b>	<b>154,323</b>
Deferred Income Tax Liability	301,053	326,718
<b>Non-Current Debt</b>	<b>890,605</b>	<b>888,391</b>
<b>Other Non-Current Liabilities</b>	<b>43,131</b>	<b>35,259</b>
<b>Total Liabilities</b>	<b>1,375,989</b>	<b>1,404,691</b>
<b>Commitments and Contingencies (note 8)</b>		
<b>Equity</b>		
Preferred stock, \$1.00 par value, 100,000 shares authorized, none issued and outstanding	-	-
Common stock, \$0.16 par value, 315,000,000 shares authorized, 217,038,267 and 216,614,407 shares issued and outstanding	34,725	34,658
Additional paid-in capital	2,597,540	2,583,885
Accumulated other comprehensive loss	(47,690)	(30,021)
Retained earnings	75,772	555,620
<b>Total Stockholders' Equity</b>	<b>2,660,347</b>	<b>3,144,142</b>
<b>Total Liabilities and Stockholders' Equity</b>	<b>\$ 4,036,336</b>	<b>\$ 4,548,833</b>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Neogen Corporation**  
**Condensed Consolidated Statements of Operations (unaudited)**  
*(in thousands, except shares)*

	Three months ended February 28/29,		Nine months ended February 28/29,	
	2025	2024	2025	2024
<b>Revenues</b>				
Product revenues	\$ 196,488	\$ 202,178	\$ 596,555	\$ 610,448
Service revenues	24,492	26,634	72,647	76,980
<b>Total Revenues</b>	<b>220,980</b>	<b>228,812</b>	<b>669,202</b>	<b>687,428</b>
<b>Cost of Revenues</b>				
Cost of product revenues	95,815	98,144	293,488	293,456
Cost of service revenues	14,900	13,785	47,193	43,554
<b>Total Cost of Revenues</b>	<b>110,715</b>	<b>111,929</b>	<b>340,681</b>	<b>337,010</b>
<b>Gross Profit</b>	<b>110,265</b>	<b>116,883</b>	<b>328,521</b>	<b>350,418</b>
<b>Operating Expenses</b>				
Sales and marketing	44,595	47,920	136,939	138,535
General and administrative	55,782	52,087	165,224	148,929
Goodwill impairment	—	—	461,390	—
Research and development	4,473	4,853	14,780	17,331
<b>Total Operating Expenses</b>	<b>104,850</b>	<b>104,860</b>	<b>778,333</b>	<b>304,795</b>
<b>Operating Income (Loss)</b>	<b>5,415</b>	<b>12,023</b>	<b>(449,812)</b>	<b>45,623</b>
<b>Other Expense</b>				
Interest income	699	1,612	2,466	5,265
Interest expense	(17,737)	(18,285)	(54,493)	(54,773)
Other, net	1,896	(1,172)	(69)	(4,021)
<b>Total Other Expense</b>	<b>(15,142)</b>	<b>(17,845)</b>	<b>(52,096)</b>	<b>(53,529)</b>
<b>Loss Before Taxes</b>	<b>(9,727)</b>	<b>(5,822)</b>	<b>(501,908)</b>	<b>(7,906)</b>
<b>Income Tax Expense (Benefit)</b>	<b>1,230</b>	<b>(3,800)</b>	<b>(22,060)</b>	<b>(3,900)</b>
<b>Net Loss</b>	<b>\$ (10,957)</b>	<b>\$ (2,022)</b>	<b>\$ (479,848)</b>	<b>\$ (4,006)</b>
<b>Net Loss Per Share</b>				
Basic	\$ (0.05)	\$ (0.01)	\$ (2.21)	\$ (0.02)
Diluted	\$ (0.05)	\$ (0.01)	\$ (2.21)	\$ (0.02)
<b>Weighted Average Shares Outstanding</b>				
Basic	217,031,907	216,597,777	216,845,782	216,438,643
Diluted	217,031,907	216,597,777	216,845,782	216,438,643

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Neogen Corporation**  
**Condensed Consolidated Statements of Comprehensive (Loss) Income (unaudited)**  
*(in thousands)*

	Three months ended February 28/29,		Nine months ended February 28/29,	
	2025	2024	2025	2024
Net loss	\$ (10,957)	\$ (2,022)	\$ (479,848)	\$ (4,006)
Other comprehensive (loss) income				
Foreign currency translation (loss) gain	(2,658)	(4,561)	(14,775)	117
Unrealized gain on marketable securities <sup>(1)</sup>	—	77	—	917
Unrealized (loss) gain on derivative instruments <sup>(2)</sup>	(287)	139	(2,894)	2,744
Other comprehensive (loss) income, net of tax:	(2,945)	(4,345)	(17,669)	3,778
Total comprehensive loss	<u>\$ (13,902)</u>	<u>\$ (6,367)</u>	<u>\$ (497,517)</u>	<u>\$ (228)</u>

<sup>(1)</sup> Amounts are net of tax of \$24 and \$290 during the three and nine months ended February 29, 2024, respectively.

<sup>(2)</sup> Amounts are net of tax of \$(91) and \$44 during the three months ended February 28, 2025 and February 29, 2024 and \$(914) and \$867 during the nine months ended February 28, 2025 and February 29, 2024, respectively.

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Neogen Corporation**  
**Condensed Consolidated Statements of Equity (unaudited)**  
*(in thousands, except shares)*

	Common Stock		Additional	Accumulated	Retained	Total
	Shares	Amount	Paid-in	Other Comprehensive Loss	Earnings	
			Capital			
<b>May 31, 2024</b>	<b>216,614,407</b>	<b>\$ 34,658</b>	<b>\$ 2,583,885</b>	<b>\$ (30,021)</b>	<b>\$ 555,620</b>	<b>\$ 3,144,142</b>
Exercise of options, RSUs and share-based compensation expense, net of taxes	4,854	1	4,017	—	—	4,018
Issuance of shares under employee stock purchase plan	78,877	13	1,028	—	—	1,041
Net loss	—	—	—	—	(12,609)	(12,609)
Other comprehensive loss	—	—	—	(1,400)	—	(1,400)
<b>August 31, 2024</b>	<b>216,698,138</b>	<b>\$ 34,672</b>	<b>\$ 2,588,930</b>	<b>\$ (31,421)</b>	<b>\$ 543,011</b>	<b>\$ 3,135,192</b>
Exercise of options, RSUs and share-based compensation expense, net of taxes	245,879	40	3,444	—	—	3,484
Net loss	—	—	—	—	(456,282)	(456,282)
Other comprehensive loss	—	—	—	(13,324)	—	(13,324)
<b>November 30, 2024</b>	<b>216,944,017</b>	<b>\$ 34,712</b>	<b>\$ 2,592,374</b>	<b>\$ (44,745)</b>	<b>\$ 86,729</b>	<b>\$ 2,669,070</b>
Exercise of options, RSUs and share-based compensation expense, net of taxes	15,478	—	4,121	—	—	4,121
Issuance of shares under employee stock purchase plan	78,772	13	1,045	—	—	1,058
Net loss	—	—	—	—	(10,957)	(10,957)
Other comprehensive loss	—	—	—	(2,945)	—	(2,945)
<b>February 28, 2025</b>	<b>217,038,267</b>	<b>\$ 34,725</b>	<b>\$ 2,597,540</b>	<b>\$ (47,690)</b>	<b>\$ 75,772</b>	<b>\$ 2,660,347</b>

  

	Common Stock		Additional	Accumulated	Retained	Total
	Shares	Amount	Paid-in	Other Comprehensive Loss	Earnings	
			Capital			
<b>May 31, 2023</b>	<b>216,245,501</b>	<b>\$ 34,599</b>	<b>\$ 2,567,828</b>	<b>\$ (33,251)</b>	<b>\$ 565,041</b>	<b>\$ 3,134,217</b>
Exercise of options, RSUs and share-based compensation expense, net of taxes	2,591	—	2,661	—	—	2,661
Issuance of shares under employee stock purchase plan	62,490	11	1,028	—	—	1,039
Net income	—	—	—	—	1,503	1,503
Other comprehensive income	—	—	—	6,755	—	6,755
<b>August 31, 2023</b>	<b>216,310,582</b>	<b>\$ 34,610</b>	<b>\$ 2,571,517</b>	<b>\$ (26,496)</b>	<b>\$ 566,544</b>	<b>\$ 3,146,175</b>
Exercise of options, RSUs and share-based compensation expense, net of taxes	209,714	34	3,477	—	—	3,511
Net loss	—	—	—	—	(3,487)	(3,487)
Other comprehensive income	—	—	—	1,368	—	1,368
<b>November 30, 2023</b>	<b>216,520,296</b>	<b>\$ 34,644</b>	<b>\$ 2,574,994</b>	<b>\$ (25,128)</b>	<b>\$ 563,057</b>	<b>\$ 3,147,567</b>
Exercise of options, RSUs and share-based compensation expense, net of taxes	15,130	2	3,749	—	—	3,751
Issuance of shares under employee stock purchase plan	72,320	11	1,212	—	—	1,223
Net loss	—	—	—	—	(2,022)	(2,022)
Other comprehensive loss	—	—	—	(4,345)	—	(4,345)
<b>February 29, 2024</b>	<b>216,607,746</b>	<b>\$ 34,657</b>	<b>\$ 2,579,955</b>	<b>\$ (29,473)</b>	<b>\$ 561,035</b>	<b>\$ 3,146,174</b>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Neogen Corporation**  
**Condensed Consolidated Statements of Cash Flows (unaudited)**  
*(in thousands)*

	Nine months ended February 28/29,	
	2025	2024
Cash Flows provided by Operating Activities		
Net loss	\$ (479,848)	\$ (4,006)
Adjustments to reconcile net loss to net cash from operating activities:		
Depreciation and amortization	89,222	87,853
Deferred income taxes	(33,113)	98
Share-based compensation	12,961	9,829
Loss on disposal of property and equipment	99	762
Amortization of debt issuance costs	2,580	2,581
Goodwill and other asset impairment	470,832	—
Other	(290)	(74)
Change in operating assets and liabilities, net of business acquisitions:		
Accounts receivable, net	9,133	(16,136)
Inventories, net	(25,124)	(48,663)
Prepaid expenses and other current assets	(6,422)	(25,170)
Accounts payable and accrued liabilities	5,985	21,386
Interest expense accrual	(7,547)	(7,711)
Change in other non-current assets and non-current liabilities	3,234	(12,232)
Net Cash provided by Operating Activities	41,702	8,517
Cash Flows used for Investing Activities		
Purchases of property, equipment and other non-current intangible assets	(88,459)	(87,167)
Proceeds from the maturities of marketable securities	325	75,319
Proceeds from the sale of property and equipment and other	4,868	62
Net Cash used for Investing Activities	(83,266)	(11,786)
Cash Flows provided by Financing Activities		
Exercise of stock options and issuance of employee stock purchase plan shares	2,242	2,443
Tax payments related to share-based awards	(1,479)	(96)
Repayment of finance lease and other	(248)	(348)
Net Cash provided by Financing Activities	515	1,999
Effects of Foreign Exchange Rate on Cash	(1,857)	(533)
Net Decrease in Cash and Cash Equivalents	(42,906)	(1,803)
Cash and Cash Equivalents, Beginning of Year	170,611	163,240
Cash and Cash Equivalents, End of Year	<u>\$ 127,705</u>	<u>\$ 161,437</u>
<b>Supplemental cash flow information</b>		
Property and equipment obtained for noncash consideration	\$ 930	\$ —
Right of use assets obtained in exchange for new operating lease liabilities	\$ 6,976	\$ 4,073

The accompanying notes are an integral part of these condensed consolidated financial statements.

**NEOGEN CORPORATION**  
**NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**  
*(Dollar amounts in thousands except shares)*

**1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION**

**DESCRIPTION OF BUSINESS**

Neogen Corporation and subsidiaries ("Neogen," "we," "our" or the "Company") develop, manufacture and market a diverse line of products and services dedicated to food and animal safety. Our Food Safety segment consists primarily of diagnostic test kits and complementary products (e.g., culture media) sold to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues and general sanitation concerns. The majority of the test kits are disposable, single-use, immunoassay and DNA detection products that rely on proprietary antibodies and RNA and DNA testing methodologies to produce rapid and accurate test results. Our expanding line of food safety products also includes genomics-based diagnostic technology, and advanced software systems that help testers objectively analyze and store, as well as perform analysis on, their results from multiple locations over extended periods.

Neogen's Animal Safety segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, cleaners, biosecurity products and genomics testing services for the worldwide animal safety market. The majority of these consumable products are marketed through veterinarians, retailers, livestock producers and animal health product distributors. Our line of drug detection products is sold worldwide for the detection of abused and therapeutic drugs in animals and animal products, and has expanded into the workplace and human forensic markets.

**BASIS OF PRESENTATION AND CONSOLIDATION**

The accompanying unaudited condensed consolidated financial statements include the accounts of Neogen and its wholly owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In our opinion, all adjustments considered necessary for a fair statement of the results of the interim period have been included in the accompanying unaudited condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended May 31, 2024.

**New Accounting Pronouncements Not Yet Adopted**

*Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which modifies the disclosure and presentation requirements of reportable segments. The amendments in the update require the disclosure of significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit and loss. The amendments also require disclosure of all other segment items by reportable segment and a description of its composition. Additionally, the amendments require disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. This update is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. We expect to adopt this guidance for our fiscal year 2025 annual reporting and are currently finalizing our assessment of the impact that this standard will have on our segment disclosures.



### *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entity's income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. This guidance becomes effective for our fiscal year 2026 annual reporting. The Company is currently evaluating the impact that this guidance will have on the presentation of its consolidated financial statements and accompanying notes.

### *Income Statement (Topic 220): Expense Disaggregation Disclosures*

In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures, which requires a public business entity to provide disaggregated disclosures, in the notes to the financial statements, of certain categories of expenses that are included in expense line items on the face of the income statement. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact that the new guidance will have on the presentation of its consolidated financial statements and accompanying notes.

## **2. REVENUE RECOGNITION**

The Company derives revenue from two primary sources—product revenue and service revenue.

Product revenue consists of shipments of:

- Diagnostic test kits, culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation;
- Consumable products marketed to veterinarians, retailers, livestock producers and animal health product distributors; and
- Biosecurity products to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.

Revenues for our products are recognized and invoiced when the product is shipped to the customer.

Service revenue consists primarily of:

- Genomic identification and related interpretive bioinformatic services;
- Neogen Analytics; and
- Other commercial laboratory services.

Revenues for Neogen's genomics and commercial laboratory services are recognized and invoiced when the applicable laboratory service is performed and the results are conveyed to the customer. Revenues for Neogen Analytics is earned ratably over the term of the underlying agreement.

Payment terms for products and services are generally 30 to 90 days.

Contract liabilities represent deposits made by customers before the satisfaction of performance obligation(s) and recognition of revenue. Upon completion of the performance obligation(s) that the Company has with the customer, the liability for the customer deposit is relieved and revenue is recognized. These customer deposits are recorded within deferred revenue on the condensed consolidated balance sheets. Changes in the balances relate primarily to sales of the Company's genomics services and Neogen Analytics.

The following table summarizes contract liabilities by period:

	Three months ended February 28/29,		Nine months ended February 28/29,	
	2025	2024	2025	2024
<b>Beginning balance</b>	\$ 5,651	\$ 4,679	\$ 4,632	\$ 4,616
Additions	3,021	5,116	10,425	11,094
Recognized into revenue	(2,903)	(4,309)	(9,288)	(10,224)
<b>Ending balance</b>	<u>\$ 5,769</u>	<u>\$ 5,486</u>	<u>\$ 5,769</u>	<u>\$ 5,486</u>

The following table presents disaggregated revenue by major product and service categories during the three and nine months ended February 28, 2025 and February 29, 2024

	Three months ended February 28/29,		Nine months ended February 28/29,	
	2025	2024	2025	2024
<b><u>Food Safety</u></b>				
Natural Toxins & Allergens	\$ 17,595	\$ 19,738	\$ 58,479	\$ 63,116
Bacterial & General Sanitation	39,882	40,395	122,317	128,393
Indicator Testing, Culture Media & Other	77,744	81,168	242,710	246,812
Biosecurity Products	11,815	10,136	35,717	32,180
Genomics Services	5,695	6,317	17,091	17,934
	<u>\$ 152,731</u>	<u>\$ 157,754</u>	<u>\$ 476,314</u>	<u>\$ 488,435</u>
<b><u>Animal Safety</u></b>				
Life Sciences	\$ 1,504	\$ 1,372	\$ 4,864	\$ 4,710
Veterinary Instruments & Disposables	15,412	17,976	45,209	47,845
Animal Care & Other	10,497	10,066	26,951	27,226
Biosecurity Products	23,827	23,055	66,557	65,694
Genomics Services	17,009	18,589	49,307	53,518
	<u>68,249</u>	<u>71,058</u>	<u>192,888</u>	<u>198,993</u>
<b>Total Revenues</b>	<u>\$ 220,980</u>	<u>\$ 228,812</u>	<u>\$ 669,202</u>	<u>\$ 687,428</u>

### 3. NET LOSS PER SHARE

Basic net loss per share was computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share was computed using the treasury stock method by dividing net loss by the weighted average number of shares of common stock outstanding.

The calculation of net loss per share follows:

	Three months ended February 28/29,		Nine months ended February 28/29,	
	2025	2024	2025	2024
Numerator for basic and diluted net loss per share:				
Net loss attributable to Neogen	\$ (10,957)	\$ (2,022)	\$ (479,848)	\$ (4,006)
Denominator for basic net loss per share:				
Weighted average shares	217,031,907	216,597,777	216,845,782	216,438,643
Effect of dilutive stock options and RSUs	—	—	—	—
Denominator for diluted net loss per share	217,031,907	216,597,777	216,845,782	216,438,643
Net loss per share:				
Basic	\$ (0.05)	\$ (0.01)	\$ (2.21)	\$ (0.02)
Diluted	\$ (0.05)	\$ (0.01)	\$ (2.21)	\$ (0.02)

Due to the net loss reported for the three and nine months ended February 28, 2025 and the three and nine months ended February 29, 2024, the stock options and RSUs were anti-dilutive.

#### 4. SEGMENT INFORMATION AND GEOGRAPHIC DATA

The Company has two reportable segments: Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services. Additionally, the Animal Safety segment produces and markets biosecurity products to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.

Many of our international operations originally focused on the Company's food safety products, and each of these units reports through the Food Safety segment. In recent years, these operations have expanded to offer the Company's complete line of products and services, including those usually associated with the Animal Safety segment such as biosecurity products, veterinary instruments and genomics services. These additional products and services are managed and directed by existing management and are reported through the Food Safety segment.

Segment information follows:

	Food Safety	Animal Safety	Corporate and Eliminations <sup>(1)</sup>	Total
<b>As of and during the three months ended February 28, 2025</b>				
Product revenues to external customers	\$ 145,248	\$ 51,240	\$ —	\$ 196,488
Service revenues to external customers	7,483	17,009	—	24,492
Total revenues to external customers	<u>\$ 152,731</u>	<u>\$ 68,249</u>	<u>\$ —</u>	<u>\$ 220,980</u>
Operating income (loss)	\$ 19,315	\$ 6,750	\$ (20,650)	\$ 5,415
Total assets	\$ 3,566,450	\$ 342,181	\$ 127,705	\$ 4,036,336
<b>As of and during the three months ended February 29, 2024</b>				
Product revenues to external customers	\$ 149,709	\$ 52,469	\$ —	\$ 202,178
Service revenues to external customers	8,045	18,589	—	26,634
Total revenues to external customers	<u>\$ 157,754</u>	<u>\$ 71,058</u>	<u>\$ —</u>	<u>\$ 228,812</u>
Operating income (loss)	\$ 15,915	\$ 14,781	\$ (18,673)	\$ 12,023
Total assets	\$ 4,071,831	\$ 344,205	\$ 166,456	\$ 4,582,492

- (1) Includes corporate assets, including cash and cash equivalents, current and deferred tax accounts and overhead expenses not allocated to specific business segments, and excludes intersegment transactions.

	Food Safety	Animal Safety	Corporate and Eliminations <sup>(1)</sup>	Total
<b>During the nine months ended February 28, 2025</b>				
Product revenues to external customers	\$ 452,974	\$ 143,581	\$ —	\$ 596,555
Service revenues to external customers	23,340	49,307	—	72,647
Total revenues to external customers	<u>\$ 476,314</u>	<u>\$ 192,888</u>	<u>\$ —</u>	<u>\$ 669,202</u>
Operating (loss) income	\$ (399,578)	\$ 8,977	\$ (59,211)	\$ (449,812)

**During the nine months ended February 29, 2024**

Product revenues to external customers	\$ 464,973	\$ 145,475	\$ —	\$ 610,448
Service revenues to external customers	23,462	53,518	—	76,980
Total revenues to external customers	<u>\$ 488,435</u>	<u>\$ 198,993</u>	<u>\$ —</u>	<u>\$ 687,428</u>
Operating income (loss)	\$ 62,485	\$ 30,876	\$ (47,738)	\$ 45,623

(1) Excludes intersegment transactions.

The following table presents the Company's revenue disaggregated by geographic location:

	Three months ended February 28/29,		Nine months ended February 28/29,	
	2025	2024	2025	2024
Domestic	\$ 115,365	\$ 124,226	\$ 333,509	\$ 348,848
International	105,615	104,586	335,693	338,580
Total revenue	<u>\$ 220,980</u>	<u>\$ 228,812</u>	<u>\$ 669,202</u>	<u>\$ 687,428</u>

## 5. GOODWILL

The following table summarizes goodwill by reportable segment:

	Food Safety	Animal Safety	Total
May 31, 2024	\$ 2,054,205	\$ 81,427	\$ 2,135,632
Impairment	(461,175)	-	(461,175)
Foreign currency translation and other	(2,108)	(644)	(2,752)
February 28, 2025	<u>\$ 1,590,922</u>	<u>\$ 80,783</u>	<u>\$ 1,671,705</u>

In the second quarter of fiscal year 2025, the Company identified that the impact of integration challenges and end market conditions on the recent overall financial performance of the Food Safety reporting unit represented a triggering event to test goodwill within that reporting unit for impairment as of September 1, 2024. Management utilized a third-party to quantitatively assess its Food Safety reporting unit. Fair value of the reporting unit was estimated based on a combination of an income-based approach, consisting of a discounted cash flows analysis, and a market-based approach, consisting of pricing multiples derived from an analysis of comparable public companies multiplied against historical and/or anticipated financial metrics of the reporting unit. The inputs to the fair value are defined in the fair value hierarchy as Level 3 inputs. Based on the results of the analysis, the carrying value of the Food Safety reporting unit exceeded its fair value as of September 1, 2024. Accordingly, an impairment charge of \$461,390 was recorded. Differences in the balance sheet change and impairment charge are due to foreign exchange.

## 6. RESTRUCTURING

The Company regularly evaluates its business and objectives to ensure that it is properly configured and sized based on changing market conditions. Accordingly, the Company has implemented certain restructuring initiatives, including consolidation of certain facilities throughout the world and rationalization of its operations. In the second quarter of fiscal year 2025, management initiated a restructuring plan to streamline operations of the Company's global genomics business.

The Company's restructuring charges consist of severance payments, costs for outplacement services, and post-employment benefits (collectively, "employee separation costs"), other related exit costs and asset impairment charges related to restructuring activities. These amounts are partially recorded within cost of service revenues and partially recorded within general and administrative expense on the condensed consolidated statements of operations.

Restructuring charges by segment were as follows:

	Three months ended February 28/29,		Nine months ended February 28/29,	
	2025	2024	2025	2024
Food Safety	\$ 305	\$ 131	\$ 1,941	\$ 347
Animal Safety	(137)	199	6,940	1,528
Corporate	—	608	1,225	1,478
Total	<u>\$ 168</u>	<u>\$ 938</u>	<u>\$ 10,106</u>	<u>\$ 3,353</u>

Restructuring activity for the nine months ended February 28, 2025 was as follows:

	Employee Separation Costs	Other Exit Costs	Total
Balance as of May 31, 2024	\$ -	\$ -	\$ -
Expense	2,420	7,686	10,106
Cash Payments	(1,727)	(490)	(2,217)
Asset impairments and other	-	(7,196)	(7,196)
Balance as of February 28, 2025	<u>\$ 693</u>	<u>\$ -</u>	<u>\$ 693</u>

## 7. INCOME TAXES

Income tax expense was \$1,230 during the three months ended February 28, 2025, and income tax benefit was \$22,060 during the nine months ended February 28, 2025. Income tax benefit was \$3,800 and \$3,900 during the three and nine months ended February 29, 2024. Income tax expense for the quarter is related to changes in the Company's forecasted pre-tax income using an estimated annualized effective tax rate. The net tax benefit for the nine month period is primarily related to pre-tax losses due to amortization expense and interest expense from the 3M FSD acquisition as well as an income tax benefit of \$9,225 associated with goodwill impairment charges. The Organization for Economic Cooperation and Development ("OECD") Pillar 2 global minimum tax rules, which generally provide for a minimum effective tax rate of 15%, are intended to apply for tax years beginning in 2024. The Company is closely monitoring developments and evaluating the impact these new rules will have on our tax rate, including eligibility to qualify for certain safe harbors. Where no safe harbor is met, the Company has included in its income tax for the three and nine months ended February 28, 2025, a forecasted amount of "top-up" tax for its foreign subsidiaries as required under the applicable rules of the countries that have adopted the Pillar Two directives.

The total amounts of unrecognized tax benefits that, if recognized, would affect the effective tax rate as of February 28, 2025 and May 31, 2024 were \$4,336 and \$2,739, respectively. Increases in unrecognized tax benefits are primarily associated with the acquired 3M FSD, including positions for transfer pricing and research and development credits.

## 8. COMMITMENTS AND CONTINGENCIES

The Company is involved in environmental remediation and monitoring activities at its Randolph, Wisconsin manufacturing facility and accrues for related costs, when such costs are determined to be probable and estimable. The Company currently utilizes a pump and treat remediation strategy, which includes semi-annual monitoring and reporting, consulting, and maintenance of monitoring wells. These annual remediation costs are expensed and have ranged from \$38 to \$131 per year over the past five years. The Company's estimated remaining liability for these costs is \$916 as of both February 28, 2025 and May 31, 2024, measured on an undiscounted basis over an estimated period of 15 years. In fiscal 2019, the Company performed an updated Corrective Measures Study on the site, per a request from the Wisconsin Department of Natural Resources ("WDNR"), and is currently working with the WDNR regarding potential alternative remediation strategies going forward. The Company believes that the current pump and treat strategy is appropriate for the site. In fiscal 2022, in collaboration with the WDNR, the Company initiated an in-situ chemical remediation pilot study, which ran over a two-year period. The results of this study were submitted to the WDNR as part of our standard annual report. If the WDNR were to require a change from the current pump and treat remediation strategy, this change could result in an increase in future costs and, ultimately, an increase in the currently recorded liability, with an offsetting charge to operations in the period recorded. The Company has recorded \$100 as a current liability as of February 28, 2025, and the remaining \$816 is recorded in other non-current liabilities in the condensed consolidated balance sheets.

In the third quarter of fiscal year 2025, the Company recorded a gain related to a settlement regarding the Company's prior acquisition of certain fixed assets. The amount of \$2,700 was received in the third quarter of fiscal year 2025. This amount was partially offset by a related fixed asset impairment of \$2,055, which was due to the asset no longer being in use. The amount was recorded within General and administrative on the condensed consolidated statements of operations within the Company's Food Safety operating segment.

Related to the Company's other contingent liabilities, a loss of \$1,400 was recorded in the third quarter of fiscal year 2025. This contingency loss was driven by an updated valuation of the performance milestone liability for the Company's CAPInnoVet, Inc. transaction. Finally, in the third quarter of fiscal year 2025, the Company reversed a liability of \$930 related to a contingent liability that was recorded as part of the Corvium, Inc. transaction. The final milestone payment was not achieved, resulting in a full reversal of the liability.

In the third quarter of fiscal year 2024, the Company received \$1,265 of business interruption insurance proceeds relating to fire damage that occurred in the fourth quarter of fiscal year 2023 at one of our Animal Safety lab facilities. The proceeds were recorded within Cost of Revenues in the condensed consolidated statements of operations.

The Company is subject to certain legal and other proceedings in the normal course of business that, in the opinion of management, are not expected to have a material effect on its future results of operations or financial position.

## 9. DERIVATIVES AND FAIR VALUE

### *Derivatives*

The Company operates on a global basis and is exposed to the risk that its financial condition, results of operations and cash flows could be adversely affected by changes in foreign currency exchange rates and changes in interest rates. To reduce the potential effects of foreign currency exchange rate movements on net earnings, the Company enters into derivative financial instruments in the form of foreign currency exchange forward contracts with major financial institutions and has also entered into interest rate swap contracts as a hedge against changes in interest rates. The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities. On the date the derivative is established, the Company designates the derivative as a cash flow hedge or as an economic hedge in accordance with its established policy. Each reporting period, derivatives are recorded at fair value in other current assets, other assets, accrued liabilities and other long-term liabilities. The change in fair value is recorded in accumulated other comprehensive loss, and amounts are reclassified into earnings on the condensed consolidated statements of operations when transactions are realized. Derivatives that are not determined to be effective hedges are adjusted to fair value with a corresponding adjustment to earnings. The Company does not enter into derivative financial instruments for trading or speculative purposes.

### *Derivatives Not Designated as Hedging Instruments*

The Company forecasts its net exposure in various receivables and payables to fluctuations in the value of various currencies, and has entered into a number of foreign currency forward contracts each month to mitigate that exposure. These contracts are recorded net at fair value on our consolidated balance sheets, classified as Level 2 in the fair value hierarchy. Gains and losses from these contracts are recognized in Other, net in our condensed consolidated statements of operations. The notional amount of forward contracts in place was \$80,254 and \$70,315 as of February 28, 2025 and May 31, 2024, respectively, and consisted of economic hedges of transactions up to April 2025.

<b>Fair Value of Derivatives Not Designated as Hedging Instruments</b>	<b>Balance Sheet Location</b>	<b>February 28, 2025</b>	<b>May 31, 2024</b>
Foreign currency forward contracts, net	Other current liabilities	\$ 350	\$ 265

The location and amount of gains (losses) from derivatives not designated as hedging instruments in our condensed consolidated statements of operations were as follows:

<b>Derivatives Not Designated as Hedging Instruments</b>	<b>Location in statements of operations</b>	<b>Three months ended February 28/29,</b>	
		<b>2025</b>	<b>2024</b>
Foreign currency forward contracts	Other, net	\$ (57)	\$ 150

<b>Derivatives Not Designated as Hedging Instruments</b>	<b>Location in statements of operations</b>	<b>Nine months ended February 28/29,</b>	
		<b>2025</b>	<b>2024</b>
Foreign currency forward contracts	Other, net	\$ (342)	\$ (391)

### *Derivatives Designated as Hedging Instruments*

In November 2022, the Company entered into a receive-variable, pay-fixed interest rate swap agreement with a \$250,000 notional value, which is designated as a cash flow hedge. In accordance with the agreement, the notional value decreased to \$200,000 in November 2024. This agreement fixed a portion of the variable interest due on our term loan facility, with an effective date of December 2, 2022 and a maturity date of June 30, 2027. Under the terms of the agreement, the Company pays a fixed interest rate of 4.215%, plus an applicable margin ranging between 150 to 225 basis points and receive a variable rate of interest based on term SOFR from the counterparty, which is reset according to the duration of the SOFR term. The fair value of the interest rate swap as of February 28, 2025 and May 31, 2024 was a net (liability) asset of (\$1,355) and \$2,451, respectively. The Company expects to reclassify a \$155 loss of accumulated other comprehensive income into earnings in the next 12 months.

We record the fair value of our interest rate swaps on a recurring basis using Level 2 observable market inputs for similar assets or liabilities in active markets.

<b>Fair Value of Derivatives Designated as Hedging Instruments</b>	<b>Balance Sheet Location</b>	<b>February 28, 2025</b>	<b>May 31, 2024</b>
Interest rate swap – current	(Other current liabilities) Prepaid expenses and other current assets	\$ (205)	\$ 2,222
Interest rate swap – non-current	Other (non-current liabilities) non-current assets	\$ (1,150)	\$ 229

### *Fair Value of Financial Instruments*

Fair value measurements are determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs. The Company utilizes a fair value hierarchy based upon the observability of inputs used in valuation techniques as follows:

Level 1: Observable inputs such as quoted prices in active markets;

Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The carrying amounts of the Company's financial instruments other than cash equivalents and marketable securities, which include accounts receivable and accounts payable, approximate fair value based on either their short maturity or current terms for similar instruments.



## 10. ACCUMULATED OTHER COMPREHENSIVE LOSS

Accumulated other comprehensive loss changes by component, net of related tax, were as follows:

	Three months ended February 28/29,		Nine months ended February 28/29,	
	2025	2024	2025	2024
<b>Accumulated other comprehensive loss, beginning balance</b>	\$ (44,745)	\$ (25,128)	\$ (30,021)	\$ (33,251)
<b>Foreign currency translation adjustment</b>				
Balance at beginning of period	\$ (44,002)	\$ (25,607)	\$ (31,885)	\$ (30,285)
Other comprehensive (loss) gain before reclassifications	(2,658)	(4,561)	(14,775)	117
Balance at end of period	<u>\$ (46,660)</u>	<u>\$ (30,168)</u>	<u>\$ (46,660)</u>	<u>\$ (30,168)</u>
<b>Marketable securities</b>				
Balance at beginning of period	\$ -	\$ (87)	\$ -	\$ (927)
Other comprehensive loss before reclassifications	-	-	-	-
Amounts reclassified from accumulated other comprehensive loss	-	77	-	917
Balance at end of period	<u>\$ -</u>	<u>\$ (10)</u>	<u>\$ -</u>	<u>\$ (10)</u>
<b>Fair value of derivatives change</b>				
Balance at beginning of period	\$ (743)	\$ 566	\$ 1,864	\$ (2,039)
Other comprehensive (loss) gain before reclassifications	(170)	731	(1,797)	4,439
Amounts reclassified from accumulated other comprehensive loss	(117)	(592)	(1,097)	(1,695)
Balance at end of period	<u>\$ (1,030)</u>	<u>\$ 705</u>	<u>\$ (1,030)</u>	<u>\$ 705</u>
<b>Accumulated other comprehensive loss, ending balance</b>	<u>\$ (47,690)</u>	<u>\$ (29,473)</u>	<u>\$ (47,690)</u>	<u>\$ (29,473)</u>

## 11. SUBSEQUENT EVENTS

On April 4, 2025, Neogen Food Safety Corporation entered into the Amendment No. 1 and Refinancing Amendment to Credit Agreement (the “Refinancing Amendment”), which amended the existing credit agreement, dated June 30, 2022. The Refinancing Amendment, among other things, provides for (i) a new tranche of senior secured term loans in an aggregate principal amount of \$450,000 (the “2025 Term Loans”) and (ii) a revolving credit facility in an aggregate principal amount of \$250,000, against which \$100,000 has been drawn (the “2025 Revolving Facility”). The 2025 Term Loans will mature on April 4, 2030. The 2025 Revolving Facility will terminate on the earlier of April 4, 2030, or the date on which the revolving commitments under the 2025 Revolving Facility are terminated. The Refinancing Amendment lowered the spread on the term loan and revolver facility borrowings from 2.35% to 1.75% based on a net leverage ratio being greater than 3.0 to 1.0. The other terms and conditions of the loan term agreement remain substantially unchanged.

On April 9, the Company announced that John Adent, the Company’s Chief Executive Officer ("CEO") and President, will be stepping down. Mr. Adent will continue to serve in his existing roles as CEO and President and as a member of the Company’s Board of Directors until his successor has been appointed. Mr. Adent and the Company entered into a CEO transition agreement (the “Transition Agreement”) in connection with the transition of Mr. Adent’s role with the Company. Pursuant to the terms of the Transition Agreement, following the appointment of his successor and until October 31, 2025 (the “Separation Date”), Mr. Adent will continue to be employed by the Company as a Special Advisor to the Board and to the Company’s new CEO.

Pursuant to the terms of the Transition Agreement, Mr. Adent will continue to participate in the Company's benefit plans and receive his base salary until the Separation Date. Mr. Adent will remain entitled to receive his annual bonus for fiscal year 2025 and will be eligible to earn a pro-rata annual bonus for fiscal year 2026, with any payment amount prorated based on the number of days from the start of the 2026 fiscal year through the Separation Date. Mr. Adent's outstanding equity incentive awards will be treated in accordance with their terms through the Separation Date. In addition, any stock option awards that are vested as of the Separation Date will remain exercisable for three years following the Separation Date or, if earlier, the full-term expiration of the stock option award. Mr. Adent will not be eligible for any grants of new equity after the date of the Transition Agreement. After the Separation Date, Mr. Adent will receive the severance compensation and benefits provided under and on terms substantially consistent with his current severance letter agreement consistent with a termination without cause; subject to him entering into a release of certain employment claims against the Company as required by the severance letter agreement.

## **PART I – FINANCIAL INFORMATION**

### **Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations**

The information in this Management’s Discussion and Analysis of Financial Condition and Results of Operations contains both historical financial information and forward-looking statements. Neogen does not provide forecasts of future financial performance. While management is optimistic about the Company’s long-term prospects, historical financial information may not be indicative of future financial results.

#### **Safe Harbor and Forward-Looking Statements**

Forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, are made throughout this Quarterly Report on Form 10-Q, including statements relating to management’s expectations regarding new product introductions; the adequacy of our sources for certain components, raw materials and finished products; and our ability to utilize certain inventory. For this purpose, any statements contained herein that are not statements of historical fact are deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. There are a number of important factors that could cause Neogen’s results to differ materially from those indicated by such forward-looking statements, including many factors beyond our control. Factors that could cause actual results to differ from those contained within forward-looking statements include (without limitation) the continued integration of the 3M food safety business and the realization of the expected benefits from that acquisition; the relationship with and performance of our transition manufacturing partner; our ability to adequately and timely remediate certain identified material weaknesses in our internal control over financial reporting; competition; recruitment and retention of key employees; impact of weather on agriculture and food production; global business disruption caused by the Russia invasion in Ukraine and related sanctions and the conflict in the Middle East; identification and integration of acquisitions; research and development risks; intellectual property protection; increasing and developing government regulation; and other risks detailed from time to time in the Company’s reports on file at the Securities and Exchange Commission, including this Quarterly Report on Form 10-Q.

In addition, any forward-looking statements represent management’s views only as of the date this Quarterly Report on Form 10-Q was first filed with the Securities and Exchange Commission and should not be relied upon as representing management’s views as of any subsequent date. Except to the extent legally required to do so, the Company specifically disclaims any obligation to update forward-looking statements, even if its views change.

#### **Trends and Uncertainties**

In prior years, production was negatively impacted by broad supply chain challenges and labor market disruptions. Additionally, input cost inflation, including increases in certain raw materials, negatively impacted operating results. In fiscal year 2024, despite a slowing rate of inflation, there were economic headwinds of softening consumer demand and higher interest rates, coupled with ongoing geopolitical tension in certain regions.

Interest rates have risen sharply, particularly in fiscal year 2023, as a way to combat inflation. This increased our borrowing costs and raised the overall cost of capital. Although the federal funds rate was reduced in 2024 and there are indications of future rate cuts, the overall interest rate we pay on our Credit Facilities remains higher than when the debt was incurred in 2022, which increases interest expense on the unhedged portion of our Term Loan. In response to the historically high inflationary environment, we took pricing actions to mitigate the impacts on the business in the prior two fiscal years. The impact of inflation continues to affect us in the current fiscal year, although at a lower rate compared to prior fiscal years.

Beginning in the first half of fiscal year 2024, we implemented a new enterprise resource planning system and exited our transition distribution agreements with 3M, which led to certain shipment delays and an elevated backlog of open orders, specifically in the Food Safety segment. At the conclusion of fiscal year 2024, order fulfillment issues were largely resolved, however, the impact of lost market share stemming from these fulfillment issues has continued in fiscal year 2025. Also in fiscal year 2025, we have experienced negative impacts from delays in restarting full production of our sample collection product line, which we relocated from 3M into a Neogen facility. However, at the end of the third quarter of this fiscal year, we resolved these delays, with production having

returned to the prior normal levels. With a change in administration in fiscal year 2025, there has been an economic policy shift towards increasing tariffs, which in turn has led and could lead to further retaliatory tariffs. These have the potential to negatively impact our international sales, as the majority of our purchases and production is done within the U.S.

Although we have no operations in or direct exposure to Russia, Belarus or Ukraine, we have experienced intermittent shortages in materials and increased costs for transportation, energy and raw materials due, in part, to the negative impact of the Russia-Ukraine military conflict, which began in February 2022, on the global economy. Our European operations and customer base have been negatively impacted by the conflict. Similarly, the military conflicts in the Middle East have increased overall geopolitical tensions. As the respective conflicts continue or worsen, they may further impact our business, financial condition or results of operations throughout fiscal year 2025.

Within the Food Safety industry, the end market continues to have a lower level of food production, partly due to significant inflation in food prices. However, there has generally been gradual end market improvement that has coincided with an increasing focus on food safety from both consumers and regulators. Within Animal Safety, the end market is at or near cyclical lows. As a result, we are optimistic about future revenue growth in the segment, particularly if the distribution channel begins to meaningfully restock inventory.

The restructuring actions undertaken in our genomics business have resulted in the voluntary attrition of revenue, following the shift in focus already made away from smaller production animals. A portion of our genomics business also serves the companion animal market, which has been experiencing weakness recently, primarily due to the impact of continued inflation, a lower number of pet adoptions, and a higher level of customer in-sourcing.

We continue to evaluate the nature and extent to which these issues impact our business, including consolidated results of operations, financial condition and liquidity. We expect these issues to continue to impact us throughout the remainder of fiscal year 2025.

### **Critical Accounting Estimates**

During the second quarter of fiscal year 2025, we incurred a goodwill impairment charge of \$461.4 million associated with our Food Safety reporting unit. Subsequent to the goodwill impairment charge, the fair value of this reporting unit approximated its carrying value. The fair value of the reporting unit is estimated based on a combination of an income approach, which utilizes discounted cash flows and a market approach, which utilizes pricing multiples derived from an analysis of comparable public companies multiplied against historical and/or anticipated financial metrics of the reporting unit. The rate used to discount the cash flows under the income approach was 10.0%. These calculations contain uncertainties as they require management to make assumptions including, but not limited to, market comparables, future cash flows of the reporting unit, and appropriate discount and long-term growth rates.

A decline in the actual cash flows of the Food Safety reporting unit in future periods, as compared to the projected cash flows used in the valuation, could result in the carrying value of this reporting unit exceeding its fair value. Further, a change in market comparables, discount rate or long-term growth rate, as a result of a change in economic conditions or otherwise could result in the carrying value of this reporting unit exceeding its fair value, which would result in an additional impairment charge.

Our critical accounting estimates are included in our Annual Report on Form 10-K for the year ended May 31, 2024 and did not materially change during the three months ended February 28, 2025.

## Executive Overview

	Three months ended February 28/29,			Nine months ended February 28/29,		
	2025	2024	Increase / (Decrease)	2025	2024	Increase / (Decrease)
Total Revenues	\$ 220,980	\$ 228,812	\$ (7,832)	\$ 669,202	\$ 687,428	\$ (18,226)
Cost of Revenues	110,715	111,929	(1,214)	340,681	337,010	3,671
Gross Profit	110,265	116,883	(6,618)	328,521	350,418	(21,897)
Operating Expenses						
Sales and marketing	44,595	47,920	(3,325)	136,939	138,535	(1,596)
General and administrative	55,782	52,087	3,695	165,224	148,929	16,295
Goodwill impairment	—	—	—	461,390	—	461,390
Research and development	4,473	4,853	(380)	14,780	17,331	(2,551)
Total Operating Expenses	104,850	104,860	(10)	778,333	304,795	473,538
Operating Income (Loss)	5,415	12,023	(6,608)	(449,812)	45,623	(495,435)
Other Expense						
Interest income	699	1,612	(913)	2,466	5,265	(2,799)
Interest expense	(17,737)	(18,285)	548	(54,493)	(54,773)	280
Other expense, net	1,896	(1,172)	3,068	(69)	(4,021)	3,952
Total Other Expense	(15,142)	(17,845)	2,703	(52,096)	(53,529)	1,433
Loss Before Taxes	(9,727)	(5,822)	(3,905)	(501,908)	(7,906)	(494,002)
Income Tax Expense (Benefit)	1,230	(3,800)	5,030	(22,060)	(3,900)	(18,160)
Net Loss	<u>\$ (10,957)</u>	<u>\$ (2,022)</u>	<u>\$ (8,935)</u>	<u>\$ (479,848)</u>	<u>\$ (4,006)</u>	<u>\$ (475,842)</u>

## Results of Operations

### Revenues

Revenue decreased \$7.8 million during the three months ended February 28, 2025 compared to the three months ended February 29, 2024. The decrease included a \$7.1 million unfavorable foreign exchange rate impact and a \$1.2 million unfavorable impact due to discontinued product lines, offset by \$0.5 million of growth in the business. The increase in the business was driven by new sales in the food quality and nutritional analysis product line paired with continued strength in indicator testing and pathogens product lines. These were partially offset by reduced sales of sample collection products due to production constraints, lower genomics volume due primarily to weakness in the companion animal market and a decline in sales of veterinary instruments, which have been impacted by tariffs.

Revenue decreased \$18.2 million during the nine months ended February 28, 2025 compared to the nine months ended February 29, 2024. The decrease included a \$21.9 million unfavorable foreign exchange rate impact and a \$1.8 million unfavorable impact due to discontinued product lines, offset by \$5.5 million of growth in the business. The year-to-date increase was driven by continued strength in indicator testing paired with new sales in the food quality and nutritional analysis product line. These increases were partially offset by production constraints within the sample collection product line and lower genomics volume, which was impacted by a shift to focus on large production animals and weakness in the companion animal market.

### *Service Revenue*

Service revenue, which consists primarily of genomics services provided to animal production and companion animal markets, was \$24.5 million and \$72.6 million during the three and nine months ended February 28, 2025 and \$26.6 million and \$77.0 million during the three and nine months ended February 29, 2024, respectively. The decrease in the three and nine months ended February 28, 2025 was primarily due to lower genomics sales into the companion animal market, as well as lower sales into the domestic poultry market, primarily due to a shift in focus towards large production animals, offset by an increase in genomics sales into beef markets.

### *International Revenue*

International sales were \$105.6 million and \$335.7 million during the three and nine months ended February 28, 2025 and \$104.6 million and \$338.6 million during the three and nine months ended February 29, 2024, respectively. The increase during the three months ended February 28, 2025 was driven by increases in the Latin American countries, partially offset by a \$7.1 million currency headwind and decreases in the Europe region. The decrease during the nine months ended February 28, 2025 was due to \$21.9 million of currency headwinds, partially offset by an increase in the Latin American countries and to a lesser extent, countries within Asia Pacific and Europe.

### **Gross Margin**

Gross margin was 49.9% and 49.1% during the three and nine months ended February 28, 2025 and 51.1% and 51.0% during the three and nine months ended February 29, 2024, respectively. The decrease in margin during the three month period was primarily due to lower volume and higher manufacturing costs related to our sample collection product line. The decrease in margin during the nine month period was primarily due to higher freight costs in the current year and \$4.6 million of restructuring charges. Additionally, a sales decline in the first and third quarters contributed to lower gross margin for the year-to-date period.

### **Operating Expenses**

#### *Sales and Marketing*

Sales and marketing expenses were \$44.6 million and \$136.9 million during the three and nine months ended February 28, 2025 and \$47.9 million and \$138.5 million during the three and nine months ended February 29, 2024, respectively. While we experienced higher shipping costs in the current year, as we took over distribution of FSD products from 3M during the second and third quarters of the prior fiscal year, these increased costs were more than offset by a decrease in fees paid to 3M for distribution services and lower royalty expense.

#### *General and Administrative*

General and administrative expenses were \$55.8 million and \$165.2 million during the three and nine months ended February 28, 2025 and \$52.1 million and \$148.9 million during the three and nine months ended February 29, 2024, respectively. For the Food Safety segment, increases compared to the prior year comparable periods were driven by a fixed asset impairment charge of \$2.1 million. For the Animal Safety segment, an increase in expense for the full year was attributable to restructuring charges, which included \$6.9 million of charges that were primarily incurred in the second quarter of the current fiscal year. Corporate expense has increased primarily due to additional headcount and higher costs associated with our prior year enterprise resource planning system implementation.

General and administrative expenses include amortization expense relating to definite-lived intangible assets of \$23.3 million and \$70.4 million during the three and nine months ended February 28, 2025 and \$23.7 million and \$71.1 million during the three and nine months ended February 29, 2024, respectively. Estimated amortization expense for fiscal years 2025 through 2029 is expected to be in the range of approximately \$90 million to \$96 million per year.

### *Goodwill Impairment*

During the nine months ended February 28, 2025, goodwill impairment charges were \$461.4 million. There were no goodwill impairment charges recorded during the prior year comparable period.

### *Research and Development*

Research and development expense was \$4.5 million and \$14.8 million during the three and nine months ended February 28, 2025 and \$4.9 million and \$17.3 million during the three and nine months ended February 29, 2024, respectively. The decrease during the three and nine months ended February 28, 2025 is primarily the result of lower contracted services and employee costs in the Food Safety segment, as we continue to realize synergies in certain areas from the 3M FSD business.

### **Other Expense**

Other expense was \$15.1 million and \$52.1 million during the three months ended February 28, 2025 and \$17.8 million and \$53.5 million during the three and nine months ended February 29, 2024, respectively. The decrease in expense during both comparable periods was due to a gain related to a settlement regarding the Company's prior acquisition of certain fixed assets. The decrease in expense was also driven by lower interest expense during both comparable periods. The lower interest expense was a result of our interest rate swap instrument. These favorable impacts were partially offset by a reduction in interest income associated with our money market portfolio.

### **Provision for Income Taxes**

Income tax expense was \$1.2 million during the three months ended February 28, 2025 and income tax benefit was \$22.1 million during the nine months ended February 28, 2025 compared to income tax benefit of \$3.8 million and \$3.9 million during the three and nine months ended February 29, 2024. Income tax expense for the quarter is related to changes in the Company's forecasted pre-tax income using an estimated annualized effective tax rate. The net tax benefit for the nine month period is primarily related to pre-tax losses due to amortization expense and interest expense from the 3M FSD acquisition as well as an income tax benefit of \$9.2 million associated with goodwill impairment charges. The Organization for Economic Cooperation and Development ("OECD") Pillar 2 global minimum tax rules, which generally provide for a minimum effective tax rate of 15%, are intended to apply for tax years beginning in 2024. We are closely monitoring developments and evaluating the impact these new rules will have on our tax rate, including eligibility to qualify for certain safe harbors. Where no safe harbor is met, we have included in our income tax for the three and nine months ended February 28, 2025, a forecasted amount of "top-up" tax for our foreign subsidiaries as required under the applicable rules of the countries that have adopted the Pillar Two directives.

### **Segment Results of Operations**

	Three months ended February 28/29,			
	2025	2024	Increase / (Decrease)	% Change
Food Safety	\$ 152,731	\$ 157,754	\$ (5,023)	(3)%
Animal Safety	68,249	71,058	(2,809)	(4)%
Total Revenues	\$ 220,980	\$ 228,812	\$ (7,832)	(3)%
Food Safety	\$ 19,315	\$ 15,915	\$ 3,400	21%
Animal Safety	6,750	14,781	(8,031)	(54)%
Segment Operating Income	\$ 26,065	\$ 30,696	\$ (4,631)	(15)%
Corporate	(20,650)	(18,673)	(1,977)	11%
Operating Income	\$ 5,415	\$ 12,023	\$ (6,608)	(55)%

	Nine months ended February 28/29,			
	2025	2024	Increase / (Decrease)	% Change
Food Safety	\$ 476,314	\$ 488,435	\$ (12,121)	(2)%
Animal Safety	192,888	198,993	(6,105)	(3)%
Total Revenues	\$ 669,202	\$ 687,428	\$ (18,226)	(3)%
Food Safety	\$ (399,578)	\$ 62,485	\$ (462,063)	(739)%
Animal Safety	8,977	30,876	(21,899)	(71)%
Segment Operating (Loss) Income	\$ (390,601)	\$ 93,361	\$ (483,962)	(518)%
Corporate	(59,211)	(47,738)	(11,473)	24%
Operating (Loss) Income	\$ (449,812)	\$ 45,623	\$ (495,435)	(1086)%

## Revenues

Revenue for the Food Safety segment decreased \$5.0 million during the three months ended February 28, 2025 compared to the three months ended February 29, 2024. The decrease was primarily due to \$6.9 million of currency headwind and \$0.5 million from discontinued product lines, partially offset by \$2.4 million of growth in the business. The increase in the business was driven by new sales in the food quality and nutritional analysis product line and strong sales in the indicator and pathogens product lines. These increases were partially offset by lower sales from the sample collection product line due to production constraints and lower sales in the culture media and general sanitation product lines.

Revenue for the Food Safety segment decreased \$12.1 million during the nine months ended February 28, 2025 compared to the nine months ended February 29, 2024. The decrease was primarily due to \$21.8 million of currency headwind and \$0.5 million from discontinued product lines, partially offset by \$10.2 million of growth in the business. The growth was driven by continued strength in indicator testing, new sales in the food quality and nutritional analysis product line and higher sales of cleaner and disinfectant products in the Europe and Latin America regions. These increases were partially offset by production constraints impacting the sample collection product line and lower sales in the natural toxins product line.

Revenue for the Animal Safety segment decreased \$2.8 million during the three months ended February 28, 2025 compared to the three months ended February 29, 2024. The decrease was due to a \$1.8 million decrease in the business, a \$0.7 million impact from discontinued product lines and a \$0.3 million unfavorable currency impact. The decline in the business was primarily related to decreased sales of veterinary instruments, which have been impacted by tariffs, and lower genomics volume, due primarily to weakness in the companion animal market. These decreases were partly offset by continued strength in rodent control products.

Revenue for the Animal Safety segment decreased \$6.1 million during the nine months ended February 28, 2025 compared to the nine months ended February 29, 2024. The decrease was primarily due to a \$4.7 million decline in the business, a \$1.3 million impact from discontinued product lines and a \$0.1 million unfavorable currency impact. The decline in the business was driven by lower genomics volume due to a shift to focus primarily on large production animals and weakness in the companion animal market paired with lower sales in the insect control and veterinary instruments product lines. These decreases were partially offset by strength in rodent control products.

## Operating Income

Operating income for the Food Safety segment increased \$3.4 million during the three months ended February 28, 2025 compared to the three months ended February 29, 2024. While revenues decreased on a quarter-to-date basis, these decreases were offset by a higher gross margin and reduced operating expenses, partially due to restructuring activities that were incurred in the second quarter of the current fiscal year.

Operating income for the Food Safety segment decreased \$462.1 million during the nine months ended February 28, 2025 compared to the nine months ended February 29, 2024. The decline was primarily due to the impairment charges of \$461.4 million in the second quarter of fiscal 2025.



Operating income for the Animal Safety segment decreased \$8.0 million during the three months ended February 28, 2025 compared to the three months ended February 29, 2024. The decline was due to both decreased sales and a reduced gross margin, as certain overhead charges increased during the quarter.

Operating income for the Animal Safety segment decreased \$21.9 million during the nine months ended February 28, 2025 compared to the nine months ended February 29, 2024. The decline was due to a decrease in sales and restructuring charges incurred primarily in the second quarter of the current fiscal year, which impacted both gross profit and operating expenses.

The increased corporate expense during each comparable period related to headcount increases, increases in equity-based compensation and costs associated with our new enterprise resource planning system.

## Non-GAAP Financial Measures

This report includes certain financial information for the Company that differs from what is reported in accordance with U.S. GAAP. These non-GAAP financial measures consist of EBITDA, Adjusted EBITDA, and Adjusted EBITDA margin. These non-GAAP financial measures are included in this report because management believes that they provide investors with additional useful information to measure the performance of the Company, and because these non-GAAP financial measures are frequently used by securities analysts, investors and other interested parties as common performance measures to compare results or estimate valuations across companies in industries the Company operates in. The Company also uses Adjusted EBITDA as a performance target to establish and award certain executive compensation awards, as disclosed in our proxy statement filed with the Securities and Exchange Commission on September 13, 2024.

### *EBITDA*

We define EBITDA as net income before interest, income taxes, and depreciation and amortization. We present EBITDA as a performance measure because it may allow for a comparison of results across periods and results across companies in the industries in which Neogen operates on a consistent basis, by removing the effects on operating performance of (a) capital structure (such as the varying levels of interest expense and interest income), (b) asset base and capital investment cycle (such as depreciation and amortization) and (c) items largely outside the control of management (such as income taxes). EBITDA also forms the basis for the measurement of Adjusted EBITDA (discussed below).

### *Adjusted EBITDA*

We define Adjusted EBITDA as EBITDA, adjusted for share-based compensation and certain other fees and expenses. We present Adjusted EBITDA because it provides an understanding of underlying business performance by excluding the following:

- Share-based compensation
- FX translation (gain)/loss on loan revaluation and other revaluation
- Certain transaction fees and integration costs
- Restructuring
- Goodwill impairment
- Contingent consideration adjustments
- ERP expense
- Other income and expense items that do not recur on a frequent or regular basis

### *Adjusted EBITDA margin*

We define Adjusted EBITDA margin as Adjusted EBITDA as a percentage of total revenues. We present Adjusted EBITDA margin as a performance measure to analyze the level of Adjusted EBITDA generated from total revenue.

These non-GAAP financial measures are presented for informational purposes only. EBITDA, Adjusted EBITDA and Adjusted EBITDA margin are not recognized terms under GAAP and should not be considered in isolation or as a substitute for, or superior to, net (loss) income, operating income, cash flow from operating activities or other measures of financial performance. This information does not purport to represent the results Neogen would have achieved had any of the transactions for which an adjustment is made occurred at the beginning of the periods presented or as of the dates indicated. This information is inherently subject to risks and uncertainties. It may not give an accurate or complete picture of Neogen's financial condition or results of operations for the periods presented and should not be relied upon when making an investment decision.

The use of the terms EBITDA, Adjusted EBITDA, and Adjusted EBITDA margin may not be comparable to similarly titled measures used by other companies or persons due to potential differences in the method of calculation.

These non-GAAP financial measures have limitations as analytical tools. For example, for EBITDA-based metrics:

- they do not reflect changes in, or cash requirements for, Neogen's working capital needs;
- they do not reflect Neogen's tax expense or the cash requirements to pay taxes;
- they do not reflect the historical cash expenditures or future requirements for capital expenditures or contractual commitments;
- they do not reflect any cash requirements for future replacements of assets that are being depreciated and amortized; and
- they may be calculated differently from other companies in Neogen's industries limiting their usefulness as comparative measures.

A reader should compensate for these limitations by relying primarily on the financial statements of Neogen and using these non-GAAP financial measures only as a supplement to evaluate Neogen's performance.

For each of these non-GAAP financial measures below, we are providing a reconciliation of the differences between the non-GAAP measure and the most directly comparable GAAP measure.

Reconciliation between net loss and EBITDA and Adjusted EBITDA and between net loss margin % and Adjusted EBITDA margin % are as follows:

	Three months ended February 28/29,		Nine months ended February 28/29,	
	2025	2024	2025	2024
Net loss	\$ (10,957)	\$ (2,022)	\$ (479,848)	\$ (4,006)
<i>Net loss margin %</i>	-5.0%	-0.9%	-71.7%	-0.6%
Income tax expense (benefit)	1,230	(3,800)	(22,060)	(3,900)
Depreciation and amortization	29,373	29,650	89,222	87,853
Interest expense, net	17,038	16,673	52,027	49,508
<b>EBITDA</b>	<b>\$ 36,684</b>	<b>\$ 40,501</b>	<b>\$ (360,659)</b>	<b>\$ 129,455</b>
Share-based compensation	4,160	3,679	12,961	9,829
FX transaction (gain) loss on loan and other revaluation <sup>(1)</sup>	(255)	638	(191)	1,350
Transaction costs <sup>(2)</sup>	518	1,103	1,636	2,360
3M integration costs <sup>(3)</sup>	662	3,807	5,450	8,930
Sample collection transition and ramp up costs <sup>(4)</sup>	2,843	541	4,676	800
Petrifilm duplicate startup costs <sup>(5)</sup>	645	—	794	—
Transformation initiatives and related costs <sup>(6)</sup>	2,438	—	3,265	—
Restructuring <sup>(7)</sup>	168	938	10,106	3,353
Goodwill impairment	—	—	461,390	—
Contingent consideration adjustments	470	(200)	470	250
ERP expense <sup>(8)</sup>	633	1,701	3,184	3,904
Other	(453)	33	526	(21)
<b>Adjusted EBITDA</b>	<b>\$ 48,513</b>	<b>\$ 52,741</b>	<b>\$ 143,608</b>	<b>\$ 160,210</b>
<i>Adjusted EBITDA margin %</i>	22.0%	23.0%	21.5%	23.3%

- (1) Net foreign currency transaction (gain) loss associated with the revaluation of foreign denominated intercompany loans and certain 3M agreements.
- (2) Includes legal, accounting, tax and other related consulting costs associated with corporate transactions and capital structure initiatives.
- (3) Includes costs associated with 3M transition agreements and related integration costs.
- (4) Includes costs associated with the transitioning of the 3M transition contract manufacturing agreement and ramp up costs associated with our sample collection product line.
- (5) Duplicate costs associated with the startup of Petrifilm manufacturing.
- (6) Includes consulting and other costs, including severance, associated with transformation initiatives.
- (7) Severance, non-cash impairment, and other related exit costs primarily associated with a reduction in our global genomics business and consolidation of certain facilities.
- (8) Expenses related to ERP implementation.

Adjusted EBITDA decreased \$4.2 million and \$16.6 million during the three and nine months ended February 28, 2025. Expressed as a percentage of revenue, Adjusted EBITDA was 22.0% and 21.5% during the three and nine months ended February 28, 2025 and 23.0% and 23.3% during the three and nine months ended February 29, 2024, respectively. The lower Adjusted EBITDA in the current year was driven primarily by lower sales and higher operating expenses compared to the prior year period.

### Financial Condition and Liquidity

Our primary sources of liquidity are cash and cash equivalents, cash flows from the operations of our business, and available borrowing capacity under our revolving facility. Our principal uses of cash include working capital-related items, capital expenditures, debt service, and strategic investments.

Our future cash generation and borrowing capacity may not be sufficient to meet cash requirements to fund the operating business, repay debt obligations, construct new manufacturing facilities, commercialize products currently under development or execute our future plans to acquire additional businesses, technology and products that fit within our strategic plan. Accordingly, we may be required, or may choose, to issue additional equity securities or enter into other financing arrangements for a portion of our future capital needs. However, we continuously monitor and forecast our liquidity situation in light of industry, customer and economic factors, and take the necessary actions to preserve our liquidity and evaluate other financial alternatives that may be available to us should the need arise. As a result, we believe that our cash flows from operations, cash on hand, and borrowing capacity will enable us to fund the operating business, repay debt obligations, construct new manufacturing facilities, commercialize products currently under development, and execute our strategic plans.

We are subject to certain legal and other proceedings in the normal course of business that have not had, and, in the opinion of management, are not expected to have, a material effect on our results of operations or financial position.

As of February 28, 2025, we had cash and cash equivalents of \$127.7 million, and borrowings available under our revolving line of credit of \$150.0 million.

In June 2022, Neogen Food Safety Corporation entered into a credit agreement consisting of a five-year senior secured term loan facility (“term loan facility”) in the amount of \$650 million and a five-year senior secured revolving facility (“revolving facility”) in the amount of \$150 million (collectively, the “Credit Facilities”). The term loan facility was drawn on August 31, 2022 while the revolving facility remained undrawn and continues to be undrawn as of February 28, 2025. In accordance with the prepayment feature, the Company paid \$100 million of the term loan facility’s principal in fiscal year 2023. The term loan facility matures on June 30, 2027 and the revolving facility matures at the earlier of June 30, 2027 or the termination of the revolving commitments.

In July 2022, Neogen Food Safety Corporation closed on an offering of \$350 million aggregate principal amount of 8.625% senior notes due in 2030.

The finance lease is a building lease that is classified within property and equipment and the current portion of debt on the condensed consolidated balance sheets as of February 28, 2025. The Company intends to elect the purchase option within the lease agreement prior to the end of the lease term.

There are no required principal payments on our Credit Facilities through fiscal year 2026. Financial covenants include maintaining specified levels of funded debt to EBITDA, and debt service coverage. As of February 28, 2025, the Company was in compliance with all financial covenants under the Credit Facilities.

#### *Cash Flows*

	Nine months ended February 28/29,		
	2025	2024	Increase (Decrease)
Net Cash provided by Operating Activities	\$ 41,702	\$ 8,517	\$ 33,185
Net Cash used for Investing Activities	\$ (83,266)	\$ (11,786)	\$ (71,480)
Net Cash provided by Financing Activities	\$ 515	\$ 1,999	\$ (1,484)

**Net Cash provided by Operating Activities**

Net cash provided by operating activities increased \$33.2 million during the nine months ended February 28, 2025 compared to the nine months ended February 29, 2024. The increase is due to improved net working capital changes, offset by a decrease in income from operations. Prior year net working capital reflected large net cash outflows due to inventory purchases, as we exited transition distribution agreements and stocked FSD inventory.

**Net Cash used for Investing Activities**

Cash used for investing activities increased \$71.5 million during the nine months ended February 28, 2025, compared to the nine months ended February 29, 2024. The increase was primarily the result of lower proceeds from marketable securities in the current year period and an increase in capital expenditures of \$1.3 million, partially offset by \$4.9 million in proceeds from the sale of a building. Capital expenditures were \$88.5 million and \$87.2 million during the nine months ended February 28, 2025 and 2024, respectively.

**Net Cash provided by Financing Activities**

Cash provided by financing activities decreased \$1.5 million during the nine months ended February 28, 2025 compared to the nine months ended February 29, 2024. The net outflow was primarily due to taxes paid on employees' share-based compensation.

We continue to make investments in our business and operating facilities. Our estimate for capital expenditures in fiscal year 2025 is \$100 million. This includes approximately \$70 million in capital expenditures related to integration of the acquired 3M FSD products, the most significant portion of which is related to the construction of, and acquisition of equipment for, our new manufacturing facility in Lansing, Michigan.

## **PART I – FINANCIAL INFORMATION**

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk**

We continuously evaluate our exposure to currency exchange and interest rate risk. There have been no meaningful changes in our exposure to risk associated with fluctuations in foreign currency exchange rates and interest rates related to our variable-rate borrowings under the Credit Facilities from that discussed in our Form 10-K.

## **PART I – FINANCIAL INFORMATION**

### **Item 4. Controls and Procedures**

#### **Evaluation of Disclosure Controls and Procedures**

The Company maintains disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

An evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of February 28, 2025 was carried out under the supervision and with the participation of the Company’s management, including the President & Chief Executive Officer and Chief Financial Officer (“the Certifying Officers”), using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control – Integrated Framework (2013). Based on the evaluation, the Certifying Officers concluded that the Company’s disclosure controls and procedures were not effective as of such date due to material weaknesses in internal control over financial reporting, referenced below.

#### **Material Weaknesses**

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.

As disclosed in Part I - Item 4 of our Quarterly Report on Form 10-Q for the quarter ended November 30, 2024, management concluded that the Company had deficiencies in the control activities and information and communication components of the COSO Framework that constitute material weaknesses, either individually or in aggregate as of November 30, 2024. These material weaknesses continue to exist as of February 28, 2025.

#### **Ongoing Remediation Efforts**

Management continues to implement measures designed to ensure that control deficiencies contributing to the material weaknesses are remediated, such that these controls are designed, implemented, and operating effectively. Our remediations actions include:

- Enhancing the design and implementation of existing control activities and developing new control activities as needed to address identified risks;
- Enhancing internal controls documentation, including retaining adequate documentary evidence for certain management review controls and maintaining evidence of precise review procedures performed to demonstrate effective operation of internal controls;
- Expanding, enhancing, and formalizing comprehensive accounting, business operations, and information technology policies and procedures;
- Developing a training program and educating control owners concerning the principles of the Internal Control - Integrated Framework (2013) issued by COSO;
- Hiring qualified personnel and outside resources to support enhanced control ownership and internal communications, including the hiring of a full-time Director of Internal Controls.

#### **Changes in Internal Controls over Financial Reporting**

Other than with respect to the remediation efforts in connection with the material weaknesses described above, no changes in our internal control over financial reporting were identified as having occurred during the quarter ended February 28, 2025 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.



## PART II – OTHER INFORMATION

### Item 1. Legal Proceedings

For a description of our material pending legal proceedings, see Note 8. “Commitments and Contingencies” of the Notes to interim condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, which is incorporated by reference.

### Item 1A. Risk Factors

This Form 10-Q should be read in conjunction with Part I Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended May 31, 2024. With the exception of the risk factors noted below, which update the risk factors in our Annual Report on Form 10-K for year ended May 31, 2024, there have been no material changes from the risk factors previously disclosed therein. The following risk factors and other information included in this report should be carefully considered. The risks and uncertainties described below are not the only ones we face; others, either unforeseen or currently deemed not material, may also have a negative impact on our Company. If any of the following occurs, our business, operating results, cash flows, and financial condition could be materially adversely affected.

***Tariffs and other trade measures could adversely affect our results of operations, financial position and cash flows.***

Our international operations subject us to discriminatory or conflicting tariffs and trade policies. As a result of the new administration's trade policy, tariffs have increased and may continue to increase our material input costs. Any further trade restrictions, retaliatory trade measures and additional tariffs could result in higher input costs to our products. We may not be able to fully mitigate the impact of these increased costs or pass price increases on to our customers. While tariffs and other trade measures imposed by other countries on U.S. goods have not yet had a significant impact on our business or results of operations, we cannot predict further developments, and such existing or future tariffs could have a material adverse effect on our results of operations, financial position and cash flows.

### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In October 2018, the Company’s Board of Directors authorized a program to purchase, subject to market conditions, up to 6,000,000 shares of the Company’s common stock. The program does not have any scheduled expiration date. As of February 28, 2025, a total of 5,900,000 shares of common stock remained available for repurchase under this program. The following is a summary of share repurchase activity during the fiscal quarter ended February 28, 2025:

Period	Shares Purchased	Average Price Paid per Share	Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares That May Yet Be Purchased Under the Plans or Programs
December 2024	—	—	—	5,900,000
January 2025	—	—	—	5,900,000
February 2025	—	—	—	5,900,000
Total	—	—	—	5,900,000

**Items 3 and 4 are not applicable or removed or reserved and have been omitted.**

### Item 5. Other Information

During the quarterly period ended February 28, 2025, no director or officer (as defined in SEC Rule 16a-1(f)) of the Company adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement (as defined in Item 408 of Regulation S-K).

## Item 6. Exhibits

### (a) Exhibit Index

31.1	<a href="#"><u>Certification of Principal Executive Officer</u></a>
31.2	<a href="#"><u>Certification of Chief Financial Officer</u></a>
32	<a href="#"><u>Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u></a>
101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

NEOGEN CORPORATION  
*(Registrant)*

Dated: April 9, 2025

/s/ John E. Adent  
John E. Adent  
President & Chief Executive Officer  
(Principal Executive Officer)

Dated: April 9, 2025

/s/ David H. Naemura  
David H. Naemura  
Chief Financial & Operating Officer  
(Chief Financial Officer)